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Introduction:

Cushing’s syndrome (CS) has been reported secondary to an
interaction between inhaled/intranasal fluticasone and low
dose ritonavir as well as other protease inhibitors (PIs) which
results in steroid accumulation, adrenal suppression and florid
1-4
CS.
There are 4 case reports of pseudo-Cushing’s syndrome (pCS) in patients taking PIs though definitive causality could not
be determined as therapy was maintained in the interest of
5
virologic control.
To our knowledge, p-CS in a HIV- infected patient secondary to
darunavir/low dose ritonavir with complete resolution following
their discontinuation has not been reported.

Case Report:

This is a 37 year old female who was started on highly active
antiretroviral therapy (HAART) with maraviroc, darunavir,
low dose ritonavir and raltegravir on
02/19/2008 (CD4-253 cells/ml / HIV
viral load-17,200copies/ml). At 3 weeks
CD4 was 446 cells/ml with viral load
down to 693 copies/ml. At that time she
complained of low grade fever, sinus
congestion with maxillary pain, cough
and headache. This resolved s/p courses
of TMP/ sulfa and levofloxacin.
On 07/11/2008 she reported 6 pound
weight gain with new central adiposity
and mild diffuse alopecia.
Nasal fluticasone was discontinued
07/30/2008 when she reported significant abdominal
obesity with breast/posterior cervical fat pad enlargement

and appearance of fat loss in her
extremities. A week later she required
hospital admission for insulin therapy
for new onset diabetes mellitus type
2. On 08/07/2008 a dramatic change
in her appearance was noted with
facial plethora, bilateral parotid
fullness, supraclavicular and posterior
cervical fat pad enlargement and
central adiposity. She noted easy
bruisability and was diagnosed with oral
candidiasis. On 09/02/2008 she required
insulin adjustment for hemoglobinA1C
of 9.3%.
On 09/08/2008 she reported ongoing substernal,
non radiating chest discomfort with facial flushing,
palpitations and shortness of breath. Work up ruled out
pheochromocytoma and carcinoid.
The diagnosis of true CS was excluded by an endocrinologist
with a normal 24 hour urine cortisol and dexamethasone
suppression test.
On 10/02/2008 after a lengthy discussion with the patient all
HAART medications were stopped.
On 10/21/2008 she reported feeling well with marked
improvement in her Cushingoid appearance. By 11/11/2008
she was off insulin with hemoglobinA1C down to 6.3%.
On 12/11/2009 she was started on maraviroc, raltegravir and
etravirine. She has had no recurrence of symptoms, despite
resumption of maraviroc and raltegravir, 2 of the 3 active
agents in the regimen she was on when her symptoms first
occurred.

Discussion:

It is vital that p-CS secondary to PIs therapy is not missed as
many of the signs/ symptoms are similar to lipodystrophy and
metabolic disease associated with HIV and HAART and it is
likely to resolve after discontinuation of the causal agent as in
this case. Further studies are required to determine if darunavir
is more likely than other PIs to cause this syndrome.
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